Cool, I think you are being more than a little optimistic with this date. The second week in July will be about the time that the second patient in the first cohort will be dosed, assuming that we have recruited a second patient by then. No safety data will be published until data from both patients in the first cohort is available. At the very earliest, that will be 6-7 weeks after the second patient is dosed.
Also, good safety data for cohort one will be good news but it will not mean that safety is assured at all doses or even at a therapeutic level. Investors/partners watching this trial may therefore wait before buying in, so these first safety result may not have as great an impact on the sp as you may think.
BLT Price at posting:
$1.10 Sentiment: None Disclosure: Held
